what-is-liquid-biopsy-test
icon-liquid-biopsy

Liquid biopsy

Enrich. Purify. Discover

A minimally invasive method of testing for biomarkers of cancer and other diseases, the liquid biopsy can sidestep costly and stressful surgical procedures. All that you require are blood samples and sensitive and specific solutions to detect and analyze circulating cell-free DNA (cfDNA), exosomes and circulating tumor cells (CTCs).

QIAGEN offers a complete, efficient and streamlined workflow to empower your liquid biopsy research. From collection through analysis, our solutions help gain deep insight into the cfDNA, CTCs and exosomes in your samples, putting you well on your way to valuable biomarker discovery.

  • Collect and stabilize samples in tubes made with a unique, non-crosslinking material designed for sensitive cfDNA
  • Get the most out of your samples with state-of-the-art cfDNA, CTC and exosome isolation technologies
  • Discover DNA mutations and RNA biomarkers with advanced next-generation sequencing and real-time qPCR solutions
  • Gain valuable insight with powerful and dedicated bioinformatics solutions

Uncover the full discovery potential of liquid biopsy

Using a simple blood sample, free-floating nucleic acids or nucleic acids from circulating cells and exosomes can reveal valuable insights into genomic drivers of cancer development or chromosome aneuploidies in fetal development research. 

QIAseq NGS products for liquid biopsy offer: 

  • Smooth integration with QIAGEN sample extraction technologies to maximize sample carry-over to NGS workflow
  • High adapter ligation efficiencies to maximize library yields
  • Even representation of the genome for in-depth genomic analysis – even from single cells
  • Specific target-enrichment of cancer-related genes
  • Sensitive detection of relevant mutations down to 1% allelic frequency

 

Figure 3. Tracking cancer’s next move: liquid biopsies could offer answers. a National Center for Biotechnology Information, www.ncbi.nlm.nih.gov/pmc/articles/PMC3794814. Infographic courtesy Qiagen.
icon-cta-blockquote2

When exosomes talk, cells listen

Exosome communication between cells is more than just idle chatter. The molecular contents of exosomes and extracellular vesicles (EVs) can provide clues to cell health, disease status and more. Learn how QIAGEN’s exosome isolation and RNA purification technologies can help advance your most challenging liquid biopsy investigations. Begin your discovery into the secrets of cell communication, cancer, aging and disease!
Learn how the Center for Genomic Medicine at the Rigshospitalet in Copenhagen, Denmark, explores novel minimally-invasive liquid biopsies to help improve cancer treatments.

Investigate the mechanisms of cancer

Circulating tumor cells (CTCs) are very important targets for cancer research. Their detection and molecular characterization enable researchers to gain new insights in the mechanism of cancer. However, detecting them against the background of normal cells in whole blood can be challenging, as it requires selective enrichment of CTCs or removal of other nucleated cells while maintaining the variability of tumor cell expression. ...

Read more

Liquid biopsies using exosomes, free-circulating nucleic acids and circulating tumor cells (CTCs)  hold the promise to transform the diagnosis and treatment of cancer as well as other diseases. QIAGEN’s liquid biopsy solutions empower you to sensitively, specifically and rapidly reveal meaningful insights from your samples with an efficient, streamlined and complete workflow for analyzing circulating cell-free DNA (ccfDNA), exosomes and CTCs, giving you the first step towards uncovering valuable biomarkers in your samples.
Wofkflow for Liquid biopsy
X
Cookies help us improve your website experience.
By using our website, you agree to our use of cookies.
Confirm